Literature DB >> 753468

The site of recurrence of non-infiltrating bladder tumours.

B H Page, V B Levison, M P Curwen.   

Abstract

A study of 56 cases of non-infiltrating bladder tumour showed a striking difference in the distribution within the bladder of the primary and the recurrent tumours. More than three-quarters of the primary tumours were confined to a restricted area near a ureteric orifice whereas only one-fifth of recurrent tumours were found in this site. By far the commonest site for recurrent tumours was the postero-superior wall of the bladder. Forty-five recurrent tumours formed in the air bubble region, a site in which no primary tumour was found in the whole series. The postero-superior wall of the bladder is subject to mild trauma and abrasion by the tip of an endoscope and the air bubble region is the recipient of hot gas produced by the diathermy. These gas bubbles may also convey detached tumour cells to the recipient site. Local trauma may encourage tumour formation either by producing a raw surface which allows implanation of tumour cells, or possibly also by reducing local resistance to the primary carcinogenic factor.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 753468     DOI: 10.1111/j.1464-410x.1978.tb02816.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  8 in total

1.  BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes.

Authors:  M D Melekos; I Zarakovitis; K Dandinis; E Fokaefs; H Chionis; H Dauaher; G Barbalias
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 2.  Superficial bladder carcinoma. Factors affecting the natural history.

Authors:  J M Fitzpatrick
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

3.  Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study.

Authors:  Masashi Matsushima; Eiji Kikuchi; Masanori Hasegawa; Kazuhiro Matsumoto; Akira Miyajima; Mototsugu Oya
Journal:  BMC Urol       Date:  2010-06-30       Impact factor: 2.264

4.  Minimization of inflammation in the treatment of bladder tumors by intravesical instillation of adriamycin.

Authors:  Y Ohi; K Okamoto; T Kawabata; A Hanafusa; C Y Fai; T Kakinoki; M Kawahara; S Asechi; N Sakamoto; S Nagata
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  In vitro and in vivo responses of a murine transitional cell carcinoma to doxorubicin, mitoxantrone and aclacinomycin-A.

Authors:  R J Ballou; M T Tseng
Journal:  Urol Res       Date:  1986

Review 6.  Update in cancer chemotherapy: genitourinary tract cancer, Part 2: Wilms' tumor and bladder cancer.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1988-02       Impact factor: 1.798

7.  Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.

Authors:  Gottfrid Sjödahl; Pontus Eriksson; Oliver Patschan; Nour-Al-Dain Marzouka; Lovisa Jakobsson; Carina Bernardo; Kristina Lövgren; Gunilla Chebil; Ellen Zwarthoff; Fredrik Liedberg; Mattias Höglund
Journal:  Int J Cancer       Date:  2019-11-14       Impact factor: 7.396

8.  Involvement of Seladin-1 in goniothalamin-induced apoptosis in urinary bladder cancer cells.

Authors:  Heng Kai Yen; Afifah-Radiah Fauzi; Laily Bin Din; Valerie J McKelvey-Martin; Chan Kok Meng; Salmaan Hussain Inayat-Hussain; Nor Fadilah Rajab
Journal:  BMC Complement Altern Med       Date:  2014-08-09       Impact factor: 3.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.